Eledon reports Q2 2026 net loss of $31.6 million, up from $11.2 million a year earlier
Eledon Pharmaceuticals reported a second-quarter 2026 net loss of $31.6 million, or $0.27 per share, compared with $11.2 million, or $0.13 per share, a year earlier. The loss was driven largely by a $9.6 million non-cash charge from changes in warrant liabilities; excluding that item, the net loss was $22.0 million versus $23.5 million. Cash and short-term investments fell to $88.8 million, which the company expects to fund operations into the second quarter of 2027.
Key points
- Q2 2026 net loss $31.6 million ($0.27 per share) vs. $11.2 million ($0.13 per share) in Q2 2025
- Non-cash warrant liability loss of $9.6 million in Q2 2026 vs. a $12.3 million gain in Q2 2025
- Excluding warrant items, net loss was $22.0 million vs. $23.5 million
- Cash, cash equivalents and short-term investments were $88.8 million at June 30, 2026, funding operations into Q2 2027
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.